Table of Contents
The Brazilian pharmaceutical sector is estimated to have grown at an average annual rate of 14.2% between 2007 and 2015, reaching revenues of US$ 23 billion. Generics have gained considerable relevance and currently represent 26% of the market compared to merely 12% in 2007. Exports only represent about 7% of sales and the sector’s trade balance has remained negative, reaching a deficit of US$ 6.6 billion in 2015. Families’ spend with health increased 114% over the past 8 years but hospital beds per inhabitant have dropped below the minimum threshold recommended by the World Health Organization. United States and European Union remain the main players in the global pharmaceutical foreign trade.
This report analyses the subject market in Brazil, its main products and services, main players’ performance and the Brazilian pharmaceutical market in the global scenario.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaPoint: Psoriatic Arthritis - Global Drug Forecast and Market Analysis to 2025 Summary Psoriatic arthritis (PsA) is a chronic immune-mediated arthritis typically affecting the large joints, especially ...
PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the ...
PharmaFocus: Tauopathies - Global Market Analysis Summary Tauopathies are a class of more than 20 neurodegenerative diseases characterized by tau protein aggregation in the brain. There are currently no ...